Irritable Bowel Syndrome Drugs Market Size & Share, by Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)}; End-user (Drug Stores & Retail, Hospital, Online Pharmacies); Product (Xifaxan, Linzess, Amitiza, Viberzi) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3040
  • Published Date: Feb 10, 2023
  • Report Format: PDF, PPT

Companies Dominating the Irritable Bowel Syndrome Drugs Landscape

top-features-companies
    • Abbott Services
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Ardelyx, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca
    • GlaxoSmithKline Plc
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Ironwood Pharmaceuticals, Inc.
    • Synergy Pharma Consultancy Private Limited
    • Synthetic Biologics, Inc 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.

  •  Indegene a provider of technology-driven healthcare solutions, and metaMe Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3040
  • Published Date: Feb 10, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of irritable bowel syndrome and growing availability of over the counter drugs are estimated to boost market growth.

The market is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2023-2035.

Lack of awareness regarding IBS treatment and the side effects of IBS drugs are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, and Johnson & Johnson Services, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, product, end user, and by region.

The IBS with diarrhea (IBS-D) segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying